Suppr超能文献

膀胱癌罕见组织学变体的临床特征与预后:一项来自中国的单中心回顾性研究

Clinical Characteristics and Prognosis of Rare Histological Variants of Bladder Cancer: A Single-Center Retrospective Study from China.

作者信息

Li Dengxiong, Li Ao, Yang Yubo, Feng Dechao, Zhang Facai, Wang Xiaoming, Bai Yunjin, Tang Yin, Han Ping

机构信息

Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, People's Republic of China.

出版信息

Cancer Manag Res. 2020 Oct 7;12:9635-9641. doi: 10.2147/CMAR.S269065. eCollection 2020.

Abstract

OBJECTIVE

To investigate the clinical characteristics and prognosis of patients with rare histological variants of bladder cancer (RHV-BC) in China.

MATERIALS AND METHODS

Patients diagnosed as bladder carcinoma with RHV in our center, from March 2009 and April 2019, were included. The univariate and multivariate COX regression model were used to evaluate the association between clinical characteristics and overall survival (OS).

RESULTS

A total of 54 (1.4%) patients with RVH-BC were identified from 3803 potential patients with bladder cancer. The RHV classifications included micropapillary variant (MPV), sarcomatoid variant (SAV), neuroendocrine variant (NEV), nested variant (NV), plasmacytoid variant (PCV), and lymphoepithelioma-like variant (LEV), which were found in 19, 18, seven, six, three, and one patient, respectively. The mean of recurrence-free survival (RFS), cancer-specific survival (CSS), and OS of patients were 18.8 months, 37.0 months and 36.0 months, respectively. The multivariable analyses indicated that metastasis and T ≥2 were independent risk factors of OS. Besides, 84.4% (27/32) of patients who were receiving intravesical therapies (IVT) suffered recurrence. Patients with adjuvant chemotherapy (AC) had a recurrence rate of 64.7% (11/17).

CONCLUSION

T≥2 and metastasis were independent risk factors of OS in patients with RHV-BC. Considering a high recurrence following transurethral resection of bladder tumor (TURBT) and IVT, early radical cystectomy (RC) might be performed for patients with RHV-BC.

摘要

目的

探讨中国罕见组织学亚型膀胱癌(RHV-BC)患者的临床特征及预后。

材料与方法

纳入2009年3月至2019年4月在本中心诊断为RHV膀胱癌的患者。采用单因素和多因素COX回归模型评估临床特征与总生存期(OS)之间的关联。

结果

从3803例潜在膀胱癌患者中,共识别出54例(1.4%)RHV-BC患者。RHV分类包括微乳头亚型(MPV)、肉瘤样亚型(SAV)、神经内分泌亚型(NEV)、巢状亚型(NV)、浆细胞样亚型(PCV)和淋巴上皮瘤样亚型(LEV),分别在19例、18例、7例、6例、3例和1例患者中发现。患者的无复发生存期(RFS)、癌症特异性生存期(CSS)和OS的平均值分别为18.8个月、37.0个月和36.0个月。多变量分析表明,转移和T≥2是OS的独立危险因素。此外,接受膀胱内治疗(IVT)的患者中有84.4%(27/32)复发。接受辅助化疗(AC)的患者复发率为64.7%(11/17)。

结论

T≥2和转移是RHV-BC患者OS的独立危险因素。考虑到经尿道膀胱肿瘤切除术(TURBT)和IVT后复发率较高,对于RHV-BC患者,可能应早期行根治性膀胱切除术(RC)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/62dc/7548230/9155f4935b40/CMAR-12-9635-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验